# Observational Small Cell Lung Carcinoma studies: 39 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials that are observational for Small Cell Lung Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational Small Cell Lung Carcinoma studies: 39 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/small-cell-lung-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 39
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07914764 | 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis | Nanjing First Hospital, Nanjing Medical University | Observational | Recruiting | Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914764) |
| October 30, 2026 | NCT07905937 | Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury | Guizhou Medical University | Observational | Recruiting | Small Cell Lung Cancer ( SCLC ), Brain Injury | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905937) |
| August 31, 2026 | NCT07795411 | Prospective Multiomic Analysis in Small-Cell Lung Cancer | Ohio State University Comprehensive Cancer Center | Observational | Recruiting | Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ), Lung Cancer, Small-Cell Lung Cancer (SCLC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795411) |
| June 26, 2026 | NCT07670442 | Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage... | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670442) |
| June 17, 2026 | NCT07652736 | A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell... | BeOne Medicines | Observational | Recruiting | Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652736) |
| May 4, 2026 | NCT07565532 | Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment | Shanghai Chest Hospital | Observational | Recruiting | Small Cell Lung Cancer ( SCLC ), Radiotherapy, Immunotherapy, Personalized Cancer Treatment | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565532) |
| April 24, 2026 | NCT07550049 | Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology | University of Kansas Medical Center | Observational | Not yet recruiting | Small Cell Lung Cancer, Head and Neck Cancer, Malignant Pleural Mesothelioma | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550049) |
| April 14, 2026 | NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | Medical University of Bialystok | Observational | Recruiting | Non-Small Cell Carcinoma of Lung, Small Cell Carcinoma of Lung | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529145) |
| April 3, 2026 | NCT07510724 | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Observational | Recruiting | Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510724) |
| March 12, 2026 | NCT07468656 | SCLC Blood Collection Study | Duke University | Observational | Not yet recruiting | Small-cell Lung Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468656) |
| February 25, 2026 | NCT07434518 | A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Observational | Recruiting | Small Cell Lung Cancer (SCLC) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07434518) |
| November 24, 2025 | NCT07244016 | Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC | Henan Cancer Hospital | Observational | Recruiting | Extensive-stage Small-cell Lung Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244016) |
| November 21, 2025 | NCT07243132 | Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study) | Sponsor not shown (see the record) | Observational | Recruiting | Metastatic Lung Cancer, Metastatic NSCLC, Metastatic Small Cell Lung Cancer | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243132) |
| September 16, 2025 | NCT07175077 | 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic... | University of Missouri-Columbia | Observational | Recruiting | Small-cell Lung Cancer, Brain Metastases | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175077) |
| September 15, 2025 | NCT07173946 | Prospective Observational Study on ES-SCLC | Peking Union Medical College Hospital | Observational | Not yet recruiting | Extensive-stage Small-cell Lung Cancer, Small Cell Lung Cancer | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173946) |
| September 15, 2025 | NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | Tianjin First Central Hospital | Observational | Not yet recruiting | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Gastrointestinal Cancers | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173244) |
| August 15, 2025 | NCT07124000 | DESTINY-PANTUMOUR04 | AstraZeneca | Observational | Recruiting | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124000) |
| July 17, 2025 | NCT07070011 | Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer | Shanghai Chest Hospital of Shanghai Jiao Tong University | Observational | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070011) |
| June 18, 2025 | NCT07026669 | A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Observational | Recruiting | Small Cell Lung Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07026669) |
| March 11, 2025 | NCT06869239 | Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid... | Peking University Cancer Hospital & Institute | Observational | Recruiting | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06869239) |
| January 17, 2025 | NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | Shanghai Pulmonary Hospital, Shanghai, China | Observational | Recruiting | Lung Cancer, Small Cell | 1,430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06780826) |
| January 14, 2025 | NCT06775002 | SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type | Fuzhou General Hospital | Observational | Not yet recruiting | Lung Cancer, Non-Small Cell, Lung Cancer Small Cell Lung Cancer (SCLC) | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775002) |
| December 10, 2024 | NCT06727370 | Cognitive Screening in Lung Cancer Patients | European Institute of Oncology | Observational | Recruiting | Lung Disease, NSCLC (Non-small Cell Lung Cancer), SCLC | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06727370) |
| December 4, 2024 | NCT06717243 | Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) | Oncology Center of Biochemical Education And Research | Observational | Recruiting | Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06717243) |
| July 23, 2024 | NCT06514118 | Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer | Qingdao Central Hospital | Observational | Recruiting | Small-cell Lung Cancer, Residual Tumor, Radiation | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06514118) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| Shanghai Chest Hospital | 2 |
| Medical University of Bialystok | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| AIO-Studien-gGmbH | 1 |
| University of Colorado, Denver | 1 |
| Fuzhou General Hospital | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| University of Kansas Medical Center | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Dana-Farber Cancer Institute | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| European Institute of Oncology | 1 |
| Qingdao Central Hospital | 1 |
| Massachusetts General Hospital | 1 |
| University of Missouri-Columbia | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Oncology Center of Biochemical Education And Research | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Peking Union Medical College Hospital | 1 |
| Cofactor Genomics, Inc. | 1 |
| Shanghai Pulmonary Hospital, Shanghai, China | 1 |
| NYU Langone Health | 1 |
| Shanghai Chest Hospital of Shanghai Jiao Tong University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 12 |
| United States | 12 |
| Germany | 2 |
| France | 2 |
| Italy | 2 |
| Poland | 1 |
| Spain | 1 |
| Greece | 1 |
| United Kingdom | 1 |
| Austria | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Import and export companies in the United States](https://specstream.ai/data/businesses/import-and-export-companies/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Tenant and eviction law firms in the United States](https://specstream.ai/data/businesses/tenant-and-eviction-law-firms/united-states)
- [Pediatric oncology practices in the United States](https://specstream.ai/data/businesses/pediatric-oncology-practices/united-states)
